{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:10:51Z","timestamp":1790683851887,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05898-2","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:38:33Z","timestamp":1789349913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world pharmacovigilance signals of antibody\u2013drug conjugates: reporting patterns by payload, linker, target, and sex in FAERS"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8836-2724","authenticated-orcid":false,"given":"Zhen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liucheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"5898_CR1","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/1078-0432.CCR-22-3949","volume":"29","author":"DP Anobile","year":"2023","unstructured":"Anobile DP, Salaroglio IC, Tabbo F, La Vecchia S, Akman M, Napoli F, Bungaro M, Benso F, Aldieri E, Bironzo P, Kopecka J, Passiglia F, Righi L, Novello S, Scagliotti GV, Riganti C (2023) Autocrine 17-beta-estradiol\/estrogen receptor-alpha loop determines the response to immune checkpoint inhibitors in non-small cell lung cancer. Clin Cancer Res 29:3958\u20133973","journal-title":"Clin Cancer Res"},{"key":"5898_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A (2022) Fcgamma receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm Res 39:89\u2013103","journal-title":"Pharm Res"},{"key":"5898_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/npp.2016.215","volume":"42","author":"TL Bale","year":"2017","unstructured":"Bale TL, Epperson CN (2017) Sex as a biological variable: who, what, when, why, and how. Neuropsychopharmacology 42:386\u2013396","journal-title":"Neuropsychopharmacology"},{"key":"5898_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jconrel.2016.11.023","volume":"246","author":"S Cazzamalli","year":"2017","unstructured":"Cazzamalli S, Corso AD, Neri D (2017) Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma. J Control Release 246:39\u201345","journal-title":"J Control Release"},{"key":"5898_CR5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156","author":"HL Chang","year":"2023","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS (2023) Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI172156","journal-title":"J Clin Invest"},{"key":"5898_CR6","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE (2024) The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov 14:2089\u20132108","journal-title":"Cancer Discov"},{"key":"5898_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100251","volume":"6","author":"F Conforti","year":"2021","unstructured":"Conforti F, Pala L, Pagan E, Corti C, Bagnardi V, Queirolo P, Catania C, De Pas T, Giaccone G (2021) Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. ESMO Open 6:100251","journal-title":"ESMO Open"},{"key":"5898_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33417","volume":"10","author":"Z Dai","year":"2024","unstructured":"Dai Z, Wang G, Zhang J, Zhao Q, Jiang L (2024) Adverse events associated with eteplirsen: a disproportionality analysis using the 2016\u20132023 FAERS data. Heliyon 10:e33417","journal-title":"Heliyon"},{"key":"5898_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","volume":"15","author":"M Dorywalska","year":"2016","unstructured":"Dorywalska M, Dushin R, Moine L, Farias SE, Zhou D, Navaratnam T, Lui V, Hasa-Moreno A, Casas MG, Tran TT, Delaria K, Liu SH, Foletti D, O\u2019Donnell CJ, Pons J, Shelton DL, Rajpal A, Strop P (2016) Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design. Mol Cancer Ther 15:958\u2013970","journal-title":"Mol Cancer Ther"},{"key":"5898_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18:327\u2013344","journal-title":"Nat Rev Clin Oncol"},{"key":"5898_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A (2023) Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 22:641\u2013661","journal-title":"Nat Rev Drug Discov"},{"key":"5898_CR12","first-page":"3183","volume":"46","author":"AA Epenetos","year":"1986","unstructured":"Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183\u20133191","journal-title":"Cancer Res"},{"issue":"1","key":"5898_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40360-023-00727-1","volume":"25","author":"JL Fisher","year":"2024","unstructured":"Fisher JL, Clark AD, Jones EF, Lasseigne BN (2024) Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes. BMC Pharmacol Toxicol 25:5","journal-title":"BMC Pharmacol Toxicol"},{"key":"5898_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107778","volume":"26","author":"Z Fu","year":"2023","unstructured":"Fu Z, Gao C, Wu T, Wang L, Li S, Zhang Y, Shi C (2023a) Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience 26:107778","journal-title":"iScience"},{"key":"5898_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101795","volume":"55","author":"Z Fu","year":"2023","unstructured":"Fu Z, Liu J, Li S, Shi C, Zhang Y (2023b) Treatment-related adverse events associated with HER2-targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. EClinicalMedicine 55:101795","journal-title":"EClinicalMedicine"},{"key":"5898_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00262-012-1369-3","volume":"62","author":"B Gorovits","year":"2013","unstructured":"Gorovits B, Krinos-Fiorotti C (2013) Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 62:217\u2013223","journal-title":"Cancer Immunol Immunother"},{"key":"5898_CR17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM (2014) The weber effect and the United States Food and Drug Administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf 37:283\u2013294","journal-title":"Drug Saf"},{"key":"5898_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40265-025-02226-5","volume":"86","author":"SM Hoy","year":"2026","unstructured":"Hoy SM (2026) Trastuzumab rezetecan: first approval. Drugs 86:111\u2013120","journal-title":"Drugs"},{"key":"5898_CR19","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1198\/jasa.2011.ap10243","volume":"106","author":"L Huang","year":"2011","unstructured":"Huang L, Zalkikar J, Tiwari RC (2011) A likelihood ratio test based method for signal detection with application to FDA\u2019s drug safety data. J Am Stat Assoc 106:1230\u20131241","journal-title":"J Am Stat Assoc"},{"key":"5898_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473916","volume":"45","author":"MD Jain","year":"2025","unstructured":"Jain MD, Abramson JS, Ansell SM (2025) Easy as ABC: managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. Am Soc Clin Oncol Educ Book 45:e473916","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"5898_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5768","volume":"33","author":"XF Jiao","year":"2024","unstructured":"Jiao XF, Pu L, Lan S, Li H, Zeng L, Wang H, Zhang L (2024) Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review. Pharmacoepidemiol Drug Saf 33:e5768","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5898_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdcr.2023.10.025","volume":"43","author":"B Khanjar","year":"2024","unstructured":"Khanjar B, Sejdiu Z, Mitre M, Mancebo S, Magro C, Harp J (2024) Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: a case series and review of the literature. JAAD Case Rep 43:40\u201350","journal-title":"JAAD Case Rep"},{"issue":"3","key":"5898_CR23","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/S1556-0864(25)00231-X","volume":"20","author":"HJS Kim","year":"2025","unstructured":"Kim HJS, Ribeiro P, Oliveira AL, Freitas HC, De Lima VCC (2025) 36P: efficacy and safety of datopotamab deruxtecan on advanced\/metastatic non-small cell lung cancer patients: a systematic review and single-arm meta-analysis. J Thorac Oncol 20:S33","journal-title":"J Thorac Oncol"},{"key":"5898_CR24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1535-7163.MCT-24-0267","volume":"24","author":"S Koganemaru","year":"2025","unstructured":"Koganemaru S, Fuchigami H, Morizono C, Shinohara H, Kuboki Y, Furuuchi K, Uenaka T, Doi T, Yasunaga M (2025) Potential mechanisms of interstitial lung disease induced by antibody-drug conjugates based on quantitative analysis of drug distribution. Mol Cancer Ther 24:242\u2013250","journal-title":"Mol Cancer Ther"},{"key":"5898_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bcp.2014.10.010","volume":"93","author":"J Li","year":"2015","unstructured":"Li J, Wan Y, Na S, Liu X, Dong G, Yang Z, Yang J, Yue J (2015) Sex-dependent regulation of hepatic CYP3A by growth hormone: roles of HNF6, C\/EBPalpha, and RXRalpha. Biochem Pharmacol 93:92\u2013103","journal-title":"Biochem Pharmacol"},{"key":"5898_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1405023","volume":"15","author":"D Liu","year":"2024","unstructured":"Liu D, Mao W, Hu B, Li X, Zhao Q, Zhang L, Hu J (2024) A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS). Front Pharmacol 15:1405023","journal-title":"Front Pharmacol"},{"key":"5898_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/antib7010010","author":"AT Lucas","year":"2018","unstructured":"Lucas AT, Price LSL, Schorzman AN, Storrie M, Piscitelli JA, Razo J, Zamboni WC (2018) Factors affecting the pharmacology of antibody-drug conjugates. Antibodies. https:\/\/doi.org\/10.3390\/antib7010010","journal-title":"Antibodies"},{"key":"5898_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","volume":"22","author":"P Ma","year":"2023","unstructured":"Ma P, Tian H, Shi Q, Liu R, Zhang Y, Qi X, Chen Y (2023) High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database. Expert Opin Drug Saf 22:685\u2013696","journal-title":"Expert Opin Drug Saf"},{"key":"5898_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111863","volume":"28","author":"L Manjarres","year":"2025","unstructured":"Manjarres L, Xavier A, Gonzalez L, Garrido C, Zacconi FC, Rivera K, Parra L, Phinikaridou A, Besa C, Andia ME (2025) Sex differences in the relationship between body composition and MASLD progression in a murine model of metabolic syndrome. iScience 28:111863","journal-title":"iScience"},{"key":"5898_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1425617","volume":"15","author":"K Mao","year":"2024","unstructured":"Mao K, Chen P, Sun H, Zhong S, Zheng H, Xu L (2024) Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). Front Pharmacol 15:1425617","journal-title":"Front Pharmacol"},{"key":"5898_CR31","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/iju5.70036","volume":"8","author":"A Matsuyama","year":"2025","unstructured":"Matsuyama A, Kato T, Kawase R, Kobayashi M, Momota A, Tsunoda Y, Yamaguchi A, Hirabayashi H, Suzuki S, Kato M (2025) Enfortumab vedotin-induced toxic epidermal necrolysis in metastatic urothelial carcinoma complicated by severe gastrointestinal bleeding. IJU Case Rep 8:348\u2013351","journal-title":"IJU Case Rep"},{"key":"5898_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s13105-023-00957-1","volume":"79","author":"R Mineiro","year":"2023","unstructured":"Mineiro R, Santos C, Goncalves I, Lemos M, Cavaco JEB, Quintela T (2023) Regulation of ABC transporters by sex steroids may explain differences in drug resistance between sexes. J Physiol Biochem 79:467\u2013487","journal-title":"J Physiol Biochem"},{"key":"5898_CR33","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1016\/j.numecd.2021.05.018","volume":"31","author":"S Palmu","year":"2021","unstructured":"Palmu S, Kuneinen S, Kautiainen H, Eriksson JG, Korhonen PE (2021) Body surface area may explain sex differences in findings from the oral glucose tolerance test among subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis 31:2678\u20132684","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"5898_CR34","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","volume":"31","author":"M Royce","year":"2025","unstructured":"Royce M, Shah M, Zhang L, Cheng J, Bonner MK, Pegues M, Miller CP, Leu L, Price LSL, Qiu J, Yu J, Truong TM, Dorff SE, Yang Y, Zhang N, Gutierrez-Lugo M, Ricks TK, Pierce WF, Luo Z, Kappel D, Goldberg KB, Shord SS, Tang S, Bhatnagar V, Pazdur R, Kluetz PG, Amiri-Kordestani L (2025) FDA approval summary: datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer. Clin Cancer Res 31:4405\u20134411","journal-title":"Clin Cancer Res"},{"key":"5898_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.40336","volume":"8","author":"L Seth","year":"2025","unstructured":"Seth L, Bhave A, Kollapaneni S, Shah V, Nahle T, Blaes A, Dent S, Hurvitz SA, Guha A (2025) Cardiotoxic effects of antibody drug conjugates vs standard chemotherapy in ERBB2-positive advanced breast cancer: a systematic review and meta-analysis. JAMA Netw Open 8:e2540336","journal-title":"JAMA Netw Open"},{"key":"5898_CR36","first-page":"92","volume":"70","author":"C Seydoux","year":"2025","unstructured":"Seydoux C, Briki M, Wagner AD, Choong E, Guidi M, Carrara S, Thoma Y, Livio F, Girardin FR, Marzolini C, Buclin T, Decosterd LA (2025) Importance of sex-dependent differences for dosing selection and optimization of chemotherapeutic drugs. Chemotherapy (Basel) 70:92\u2013101","journal-title":"Chemotherapy (Basel)"},{"key":"5898_CR37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41593-021-00806-8","volume":"24","author":"RM Shansky","year":"2021","unstructured":"Shansky RM, Murphy AZ (2021) Considering sex as a biological variable will require a global shift in science culture. Nat Neurosci 24:457\u2013464","journal-title":"Nat Neurosci"},{"key":"5898_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241299935","volume":"18","author":"J Shi","year":"2024","unstructured":"Shi J, Liu X, Wu L, Jiang Y, Zhang Y, Wang Y (2024) Interstitial lung disease with antibody-drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014-2023. Ther Adv Respir Dis 18:17534666241299935","journal-title":"Ther Adv Respir Dis"},{"key":"5898_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","volume":"10","author":"Y Shu","year":"2022","unstructured":"Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q (2022) Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health 10:996179","journal-title":"Front Public Health"},{"key":"5898_CR40","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.1021\/acs.molpharmaceut.9b00437","volume":"16","author":"IK Sokka","year":"2019","unstructured":"Sokka IK, Ekholm FS, Johansson MP (2019) Increasing the potential of the auristatin cancer-drug family by shifting the conformational equilibrium. Mol Pharm 16:3600\u20133608","journal-title":"Mol Pharm"},{"key":"5898_CR41","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.cell.2022.04.012","volume":"185","author":"NS Stachenfeld","year":"2022","unstructured":"Stachenfeld NS, Mazure CM (2022) Precision medicine requires understanding how both sex and gender influence health. Cell 185:1619\u20131622","journal-title":"Cell"},{"key":"5898_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrc2394","volume":"8","author":"K Strebhardt","year":"2008","unstructured":"Strebhardt K, Ullrich A (2008) Paul Ehrlich\u2019s magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473\u2013480","journal-title":"Nat Rev Cancer"},{"key":"5898_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-025-01720-3","volume":"18","author":"HN Tan","year":"2025","unstructured":"Tan HN, Morcillo MA, Lopez J, Minchom A, Sharp A, Paschalis A, Silva-Fortes G, Raobaikady B, Banerji U (2025) Treatment-related adverse events of antibody drug-conjugates in clinical trials. J Hematol Oncol 18:71","journal-title":"J Hematol Oncol"},{"key":"5898_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10555-024-10231-5","volume":"44","author":"SC Tang","year":"2025","unstructured":"Tang SC, Wynn C, Le T, McCandless M, Zhang Y, Patel R, Maihle N, Hillegass W (2025) Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: a systematic review and meta-analysis. Cancer Metastasis Rev 44:18","journal-title":"Cancer Metastasis Rev"},{"key":"5898_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102546","volume":"116","author":"A Tolcher","year":"2023","unstructured":"Tolcher A, Hamilton E, Coleman RL (2023) The evolving landscape of antibody-drug conjugates in gynecologic cancers. Cancer Treat Rev 116:102546","journal-title":"Cancer Treat Rev"},{"key":"5898_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM (2024) Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 21:203\u2013223","journal-title":"Nat Rev Clin Oncol"},{"key":"5898_CR47","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","volume":"85","author":"Q Wei","year":"2025","unstructured":"Wei Q, Yang T, Zhang Z, Wang F, Yang Y, Zhu J, Zhu X, Li Y, Xing Y, Lu Y, Tian X, Fan M, Zhang Y, Xue X, Li M, Yu C, Wang L, Shimura T, Fang J, Cao Z, Ying J, Guo P, Cheng X (2025) Perivascular niche-resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment. Cancer Res 85:2081\u20132099","journal-title":"Cancer Res"},{"key":"5898_CR48","doi-asserted-by":"publisher","first-page":"1000119","DOI":"10.4172\/2157-7609.1000119","volume":"3","author":"L Yang","year":"2012","unstructured":"Yang L, Li Y, Hong H, Chang CW, Guo LW, Lyn-Cook B, Shi L, Ning B (2012) Sex differences in the expression of drug-metabolizing and transporter genes in human liver. J Drug Metab Toxicol 3:1000119","journal-title":"J Drug Metab Toxicol"},{"key":"5898_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15679-x","volume":"11","author":"Y Ye","year":"2020","unstructured":"Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, Han L (2020) Sex-associated molecular differences for cancer immunotherapy. Nat Commun 11:1779","journal-title":"Nat Commun"},{"key":"5898_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2016.04.001","volume":"29","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills GB, Shu Y, Li L, Liang H (2016) Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell 29:711\u2013722","journal-title":"Cancer Cell"},{"key":"5898_CR51","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/JS9.0000000000003314","volume":"112","author":"X Zheng","year":"2026","unstructured":"Zheng X, Song Y, Cao Y, Zhang X, Ge K, Zhang Q, Wang Y, Zhang H, Li S, Cao L, Wang L (2026) Systematic analysis and mechanistic investigation of cardiac adverse events associated with antibody-drug conjugates using FAERS database. Int J Surg 112:1436\u20131447","journal-title":"Int J Surg"},{"key":"5898_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H (2023) Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer 129:283\u2013295","journal-title":"Cancer"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05898-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05898-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:38:35Z","timestamp":1789349915000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05898-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":52,"alternative-id":["5898"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05898-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}